Lista de obras - Monika E Hegi - Dominio Público Uruguay

-OMICS AND PROGNOSTIC MARKERS

artículo científico publicado en 2011

A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature

artículo científico publicado en 2012

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)

artículo científico publicado en 2012

Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.

artículo científico publicado en 2012

Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation.

artículo científico publicado en 1994

Analysis of activated protooncogenes in B6C3F1 mouse liver tumors induced by ciprofibrate, a potent peroxisome proliferator.

artículo científico publicado en 1993

Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1.

artículo científico publicado en 2002

Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.

artículo científico publicado en 2008

Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22

artículo científico publicado el 13 de noviembre de 1992

Brain cancer in 2012: Molecular characterization leads the way.

artículo científico

CSIG-05THE UBIQUITIN SPECIFIC PEPTIDASE 15 (USP15) SUPPRESSES PROLIFERATION OF HUMAN GLIOBLASTOMA CELL LINES VIA STABILIZATION OF HECTD1 E3 LIGASE.

artículo científico publicado en 2015

Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice.

artículo científico publicado en 1993

Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma

artículo científico publicado en 2015

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

artículo científico publicado en 2014

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome

artículo científico publicado en 2016

Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes.

artículo científico publicado en 2003

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

artículo científico publicado en 2004

Combining chromosomal arm status and significantly aberrant genomic locations reveals new cancer subtypes

artículo científico publicado en 2009

Comparison of pulmonary O6-methylguanine DNA adduct levels and Ki-ras activation in lung tumors from resistant and susceptible mouse strains.

artículo científico publicado en 1993

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

artículo científico publicado en 2008

Correlation of immune phenotype with IDH mutation in diffuse glioma.

artículo científico publicado en 2017

Correlative studies in neuro-oncology trials: should they influence treatment?

artículo científico publicado en 2006

Current concepts and management of glioblastoma

artículo científico publicado en 2011

Current management of low-grade gliomas

artículo científico publicado en 2016

DNA fingerprinting of glioma cell lines and considerations on similarity measurements.

artículo científico publicado en 2012

Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas.

artículo científico publicado en 1997

Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma

artículo científico publicado en 2016

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial

scientific article published on 07 October 2013

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

scientific article published on 08 December 2020

EG-05COMBINATION OF GENE COPY GAIN AND EPIGENETIC DEREGULATION ARE ASSOCIATED WITH THE ABERRANT EXPRESSION OF A STEM CELL RELATED HOX-SIGNATURE IN GLIOBLASTOMA.

artículo científico publicado en 2014

EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma

artículo científico publicado en 2012

Early detection of human glioma sphere xenografts in mouse brain using diffusion MRI at 14.1 T.

artículo científico publicado en 2016

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial

artículo científico publicado en 2017

Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome

artículo científico publicado en 2009

Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization.

artículo científico publicado en 2007

Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments

artículo científico publicado en 2008

Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and

article

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.

artículo científico publicado en 2017

Evidence-based management of adult patients with diffuse glioma - Authors' reply

artículo científico publicado en 2017

Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma.

artículo científico publicado en 2010

Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.

artículo científico publicado en 2018

Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.

artículo científico publicado en 2010

Familial Brain Tumour Syndrome Associated with a p53 Germline Deletion of Codon 236

artículo científico publicado en 1995

GENETIC AND EPIGENETIC DEREGULATION ARE ASSOCIATED WITH THE ABERRANT EXPRESSION OF A STEM CELL RELATED HOX GENE SIGNATURE IN GLIOBLASTOMA.

artículo científico publicado en 2014

Genetic alterations in brain tumors following 1,3-butadiene exposure in B6C3F1 mice

artículo científico publicado en 2005

Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison

artículo científico publicado en 2015

Glioma epigenetics: From subclassification to novel treatment options

artículo científico publicado en 2017

Growth promoting signaling by tenascin-C [corrected].

artículo científico publicado en 2004

Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas.

artículo científico publicado en 1997

Hepatic and pulmonary carcinogenicity of methylene chloride in mice: a search for mechanisms.

artículo científico publicado en 1995

Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors: a translational research project of the European Organization for Research and T

artículo científico publicado en 2006

INK4a/Arf is required for suppression of EGFR/DeltaEGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma.

artículo científico publicado en 2004

Identical mutations of the p53 tumor suppressor gene in the gliomatous and the sarcomatous components of gliosarcomas suggest a common origin from glial cells.

artículo científico publicado en 1995

Improving survival in molecularly selected glioblastoma

artículo científico publicado en 2019

In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice

artículo científico publicado en 1993

In vivo characterization of brain metabolism by 1 H MRS, 13 C MRS and 18 FDG PET reveals significant glucose oxidation of invasively growing glioma cells

artículo científico publicado en 2018

In-vitro assays to detect alkylating and mutagenic activities of dietary components nitrosated in situ

artículo científico publicado en 1987

Individualized targeted therapy for glioblastoma: fact or fiction?

artículo científico publicado en 2012

Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells

artículo científico publicado en 2020

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.

artículo científico publicado en 2017

Light-induced cell death of retinal photoreceptors in the absence of p53

artículo científico publicado en 1998

MGMT gene silencing and benefit from temozolomide in glioblastoma

artículo científico publicado en 2005

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

artículo científico publicado en 2009

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges

artículo científico publicado en 2019

MGMT testing--the challenges for biomarker-based glioma treatment

artículo científico publicado en 2014

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial

artículo científico publicado en 2015

Marker-independent identification of glioma-initiating cells

artículo científico publicado en 2010

Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM

scientific article published on 03 July 2019

Methylguanine methyltransferase testing in glioblastoma: when and how?

artículo científico publicado en 2007

Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact

artículo científico publicado en 2015

Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia

artículo científico publicado en 2009

Molecular diagnostics of gliomas: the clinical perspective

artículo científico publicado en 2010

Molecular insights into brain tumors: ready for translation into novel treatment strategies?

artículo científico publicado en 2013

Molecular neuro-oncology in clinical practice: a new horizon

artículo científico publicado en 2013

Neuro-oncology: in search of molecular markers of glioma in elderly patients.

artículo científico publicado en 2013

Neuro-oncology: oligodendroglioma and molecular markers

artículo científico publicado en 2007

New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.

artículo científico publicado en 2012

New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.

artículo científico publicado en 2006

No complementation between TP53 or RB-1 and v-src in astrocytomas of GFAP-v-src transgenic mice

artículo científico publicado en 1999

No measurable increase in thymidine glycol or 8-hydroxydeoxyguanosine in liver DNA of rats treated with nafenopin or choline-devoid low-methionine diet

artículo científico publicado en 1990

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

artículo científico publicado en 2007

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.

artículo científico publicado en 2018

Optimal role of temozolomide in the treatment of malignant gliomas.

artículo científico publicado en 2005

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice

artículo científico publicado en 2012

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

artículo científico publicado en 2010

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).

artículo científico publicado en 2016

Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival.

artículo científico publicado en 2010

Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial

artículo científico

Prognostic factors for low-grade gliomas.

artículo científico publicado en 2003

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

artículo científico publicado en 2014

Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

artículo científico publicado en 2018

Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas.

artículo científico publicado en 2001

RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study

artículo científico publicado en 2009

Radiotherapy suppresses angiogenesis in mice through TGF-betaRI/ALK5-dependent inhibition of endothelial cell sprouting

artículo científico publicado en 2010

Recent developments in the use of chemotherapy in brain tumours.

artículo científico publicado en 2006

Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant.

artículo científico publicado en 2000

Reply to F. Felix et al and M.F. Fay et al.

artículo científico publicado en 2016

Reply to M.C. Chamberlain

artículo científico publicado en 2014

Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells

artículo científico publicado en 2022

Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors.

artículo científico publicado en 2016

Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?

scientific article published on September 2010

Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma

artículo científico publicado en 2008

Targeting brain-tumor stem cells

artículo científico publicado en 2007

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

artículo científico publicado en 2016

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

artículo científico publicado en 2012

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.

artículo científico publicado en 2018

The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation

scientific article published on 01 March 2019

The mouse ERG before and after light damage is independent of p53

artículo científico publicado en 1998

Toward methylation-based classification of central nervous system tumors

artículo científico publicado en 2018

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

artículo científico publicado en 2015

Ubiquitin Specific Peptidase 15 (USP15) suppresses glioblastoma cell growth via stabilization of HECTD1 E3 ligase attenuating WNT pathway activity.

artículo científico publicado en 2017

Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

artículo científico publicado en 2008

WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1.

artículo científico publicado en 2015

Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?

artículo científico publicado en 2015

[Role of MGMT and clinical applications in brain tumours].

artículo científico publicado en 2007

p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma.

artículo científico publicado en 2000

p53 transdominance but no gain of function in mouse brain tumor model

artículo científico publicado en 2000

p73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade.

artículo científico publicado en 2001

Lista de obras de Monika E Hegi

-OMICS AND PROGNOSTIC MARKERS

A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)

Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.

Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation.

Analysis of activated protooncogenes in B6C3F1 mouse liver tumors induced by ciprofibrate, a potent peroxisome proliferator.

Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1.

Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.

Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22

Brain cancer in 2012: Molecular characterization leads the way.

CSIG-05THE UBIQUITIN SPECIFIC PEPTIDASE 15 (USP15) SUPPRESSES PROLIFERATION OF HUMAN GLIOBLASTOMA CELL LINES VIA STABILIZATION OF HECTD1 E3 LIGASE.

Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice.

Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome

Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes.

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

Combining chromosomal arm status and significantly aberrant genomic locations reveals new cancer subtypes

Comparison of pulmonary O6-methylguanine DNA adduct levels and Ki-ras activation in lung tumors from resistant and susceptible mouse strains.

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

Correlation of immune phenotype with IDH mutation in diffuse glioma.

Correlative studies in neuro-oncology trials: should they influence treatment?

Current concepts and management of glioblastoma

Current management of low-grade gliomas

DNA fingerprinting of glioma cell lines and considerations on similarity measurements.

Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas.

Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

EG-05COMBINATION OF GENE COPY GAIN AND EPIGENETIC DEREGULATION ARE ASSOCIATED WITH THE ABERRANT EXPRESSION OF A STEM CELL RELATED HOX-SIGNATURE IN GLIOBLASTOMA.

EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma

Early detection of human glioma sphere xenografts in mouse brain using diffusion MRI at 14.1 T.

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial

Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome

Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization.

Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments

Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.

Evidence-based management of adult patients with diffuse glioma - Authors' reply

Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma.

Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.

Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.

Familial Brain Tumour Syndrome Associated with a p53 Germline Deletion of Codon 236

GENETIC AND EPIGENETIC DEREGULATION ARE ASSOCIATED WITH THE ABERRANT EXPRESSION OF A STEM CELL RELATED HOX GENE SIGNATURE IN GLIOBLASTOMA.

Genetic alterations in brain tumors following 1,3-butadiene exposure in B6C3F1 mice

Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison

Glioma epigenetics: From subclassification to novel treatment options

Growth promoting signaling by tenascin-C [corrected].

Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas.

Hepatic and pulmonary carcinogenicity of methylene chloride in mice: a search for mechanisms.

Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors: a translational research project of the European Organization for Research and T

INK4a/Arf is required for suppression of EGFR/DeltaEGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma.

Identical mutations of the p53 tumor suppressor gene in the gliomatous and the sarcomatous components of gliosarcomas suggest a common origin from glial cells.

Improving survival in molecularly selected glioblastoma

In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice

In vivo characterization of brain metabolism by 1 H MRS, 13 C MRS and 18 FDG PET reveals significant glucose oxidation of invasively growing glioma cells

In-vitro assays to detect alkylating and mutagenic activities of dietary components nitrosated in situ

Individualized targeted therapy for glioblastoma: fact or fiction?

Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.

Light-induced cell death of retinal photoreceptors in the absence of p53

MGMT gene silencing and benefit from temozolomide in glioblastoma

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges

MGMT testing--the challenges for biomarker-based glioma treatment

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial

Marker-independent identification of glioma-initiating cells

Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM

Methylguanine methyltransferase testing in glioblastoma: when and how?

Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact

Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia

Molecular diagnostics of gliomas: the clinical perspective

Molecular insights into brain tumors: ready for translation into novel treatment strategies?

Molecular neuro-oncology in clinical practice: a new horizon

Neuro-oncology: in search of molecular markers of glioma in elderly patients.

Neuro-oncology: oligodendroglioma and molecular markers

New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.

New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.

No complementation between TP53 or RB-1 and v-src in astrocytomas of GFAP-v-src transgenic mice